Green fluorescent protein as a selectable marker of fibronectin-facilitated retroviral gene transfer in primary human T lymphocytes

Valérie Dardalhon, Nelly Noraz, Karen Pollok, Cosette Rebouissou, Myriam Boyer, Arjen Q. Bakker, Hergen Spits, Naomi Taylor

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The success of gene therapy strategies for congenital and acquired blood disorders requires high levels of gene transfer into hematopoietic cells. Retroviral vectors have been extensively used to deliver foreign genes to mammalian cells and improvement of transduction protocols remains dependent on markers that can be rapidly monitored and used for efficient selection of transduced cells. The enhanced green fluorescent protein (EGFP) is a suitable reporter molecule for gene expression because of its lack of cytotoxicity and stable fluorescence signal that can be readily detected by flow cytometry. However, attempts to adapt the GFP system to stable transduction of human lymphocytes have not been satisfactory. In this article, transductions of primary human T lymphocytes were performed using cell-free supernatants from a PG13 packaging cell line in which a retroviral vector expressing EGFP was pseudotyped with the gibbon ape leukemia virus (GALV) envelope. Using this system combined with a fibronectin-facilitated protocol, primary lymphocytes were transduced with a mean gene transfer efficiency of 27.5% following a 2-day stimulation with either PHA or anti-CD3/CD28 antibodies. Conditions that increased the entry of lymphocytes into cell cycle did not consistently correlate with enhanced gene transfer, indicating that factors other than proliferation are important for optimal retroviral gene transfer. These results demonstrate the utility of EGFP as a marker for human T cell transduction and will enable further optimization of T cell gene therapy protocols.

Original languageEnglish
Pages (from-to)5-14
Number of pages10
JournalHuman Gene Therapy
Volume10
Issue number1
DOIs
StatePublished - Jan 1 1999

Fingerprint

Green Fluorescent Proteins
Fibronectins
T-Lymphocytes
Genes
Lymphocytes
Genetic Therapy
Gibbon ape leukemia virus
Transfer Factor
Product Packaging
Cell- and Tissue-Based Therapy
Reporter Genes
Cell Cycle
Flow Cytometry
Fluorescence
Gene Expression
Cell Line
Antibodies
enhanced green fluorescent protein

ASJC Scopus subject areas

  • Genetics

Cite this

Green fluorescent protein as a selectable marker of fibronectin-facilitated retroviral gene transfer in primary human T lymphocytes. / Dardalhon, Valérie; Noraz, Nelly; Pollok, Karen; Rebouissou, Cosette; Boyer, Myriam; Bakker, Arjen Q.; Spits, Hergen; Taylor, Naomi.

In: Human Gene Therapy, Vol. 10, No. 1, 01.01.1999, p. 5-14.

Research output: Contribution to journalArticle

Dardalhon, Valérie ; Noraz, Nelly ; Pollok, Karen ; Rebouissou, Cosette ; Boyer, Myriam ; Bakker, Arjen Q. ; Spits, Hergen ; Taylor, Naomi. / Green fluorescent protein as a selectable marker of fibronectin-facilitated retroviral gene transfer in primary human T lymphocytes. In: Human Gene Therapy. 1999 ; Vol. 10, No. 1. pp. 5-14.
@article{5809646562124851a05ae443d96241a0,
title = "Green fluorescent protein as a selectable marker of fibronectin-facilitated retroviral gene transfer in primary human T lymphocytes",
abstract = "The success of gene therapy strategies for congenital and acquired blood disorders requires high levels of gene transfer into hematopoietic cells. Retroviral vectors have been extensively used to deliver foreign genes to mammalian cells and improvement of transduction protocols remains dependent on markers that can be rapidly monitored and used for efficient selection of transduced cells. The enhanced green fluorescent protein (EGFP) is a suitable reporter molecule for gene expression because of its lack of cytotoxicity and stable fluorescence signal that can be readily detected by flow cytometry. However, attempts to adapt the GFP system to stable transduction of human lymphocytes have not been satisfactory. In this article, transductions of primary human T lymphocytes were performed using cell-free supernatants from a PG13 packaging cell line in which a retroviral vector expressing EGFP was pseudotyped with the gibbon ape leukemia virus (GALV) envelope. Using this system combined with a fibronectin-facilitated protocol, primary lymphocytes were transduced with a mean gene transfer efficiency of 27.5{\%} following a 2-day stimulation with either PHA or anti-CD3/CD28 antibodies. Conditions that increased the entry of lymphocytes into cell cycle did not consistently correlate with enhanced gene transfer, indicating that factors other than proliferation are important for optimal retroviral gene transfer. These results demonstrate the utility of EGFP as a marker for human T cell transduction and will enable further optimization of T cell gene therapy protocols.",
author = "Val{\'e}rie Dardalhon and Nelly Noraz and Karen Pollok and Cosette Rebouissou and Myriam Boyer and Bakker, {Arjen Q.} and Hergen Spits and Naomi Taylor",
year = "1999",
month = "1",
day = "1",
doi = "10.1089/10430349950019147",
language = "English",
volume = "10",
pages = "5--14",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Green fluorescent protein as a selectable marker of fibronectin-facilitated retroviral gene transfer in primary human T lymphocytes

AU - Dardalhon, Valérie

AU - Noraz, Nelly

AU - Pollok, Karen

AU - Rebouissou, Cosette

AU - Boyer, Myriam

AU - Bakker, Arjen Q.

AU - Spits, Hergen

AU - Taylor, Naomi

PY - 1999/1/1

Y1 - 1999/1/1

N2 - The success of gene therapy strategies for congenital and acquired blood disorders requires high levels of gene transfer into hematopoietic cells. Retroviral vectors have been extensively used to deliver foreign genes to mammalian cells and improvement of transduction protocols remains dependent on markers that can be rapidly monitored and used for efficient selection of transduced cells. The enhanced green fluorescent protein (EGFP) is a suitable reporter molecule for gene expression because of its lack of cytotoxicity and stable fluorescence signal that can be readily detected by flow cytometry. However, attempts to adapt the GFP system to stable transduction of human lymphocytes have not been satisfactory. In this article, transductions of primary human T lymphocytes were performed using cell-free supernatants from a PG13 packaging cell line in which a retroviral vector expressing EGFP was pseudotyped with the gibbon ape leukemia virus (GALV) envelope. Using this system combined with a fibronectin-facilitated protocol, primary lymphocytes were transduced with a mean gene transfer efficiency of 27.5% following a 2-day stimulation with either PHA or anti-CD3/CD28 antibodies. Conditions that increased the entry of lymphocytes into cell cycle did not consistently correlate with enhanced gene transfer, indicating that factors other than proliferation are important for optimal retroviral gene transfer. These results demonstrate the utility of EGFP as a marker for human T cell transduction and will enable further optimization of T cell gene therapy protocols.

AB - The success of gene therapy strategies for congenital and acquired blood disorders requires high levels of gene transfer into hematopoietic cells. Retroviral vectors have been extensively used to deliver foreign genes to mammalian cells and improvement of transduction protocols remains dependent on markers that can be rapidly monitored and used for efficient selection of transduced cells. The enhanced green fluorescent protein (EGFP) is a suitable reporter molecule for gene expression because of its lack of cytotoxicity and stable fluorescence signal that can be readily detected by flow cytometry. However, attempts to adapt the GFP system to stable transduction of human lymphocytes have not been satisfactory. In this article, transductions of primary human T lymphocytes were performed using cell-free supernatants from a PG13 packaging cell line in which a retroviral vector expressing EGFP was pseudotyped with the gibbon ape leukemia virus (GALV) envelope. Using this system combined with a fibronectin-facilitated protocol, primary lymphocytes were transduced with a mean gene transfer efficiency of 27.5% following a 2-day stimulation with either PHA or anti-CD3/CD28 antibodies. Conditions that increased the entry of lymphocytes into cell cycle did not consistently correlate with enhanced gene transfer, indicating that factors other than proliferation are important for optimal retroviral gene transfer. These results demonstrate the utility of EGFP as a marker for human T cell transduction and will enable further optimization of T cell gene therapy protocols.

UR - http://www.scopus.com/inward/record.url?scp=0032958546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032958546&partnerID=8YFLogxK

U2 - 10.1089/10430349950019147

DO - 10.1089/10430349950019147

M3 - Article

VL - 10

SP - 5

EP - 14

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 1

ER -